-
Oil extends gains, stocks drop as peace talk hopes fade
-
Bill legalising assisted dying in England and Wales set to fail
-
Chinese EVs, flying cars take centre stage at world's biggest auto show
-
Macron says still sees France, Germany developing European fighter jet
-
Al Ahli star Mahrez warns team-mates not to take Japanese rivals for granted
-
Greece expands sunbed-free beach list for 2026
-
Rugby legend McCaw hails 'spectacular' NZ stadium built after deadly quake
-
Mideast war drives up condom, rubber glove prices: manufacturers
-
Gulf states in limbo as US-Iran crisis drags on
-
Liverpool's Slot warns 'margins are small' in Champions League push
-
Musk says Tesla has started 'robotaxi' production
-
Suspected Nazi-looted Stradivarius reappears in France, says expert
-
Glacier block delays route-setting on Everest
-
China's DeepSeek releases long-awaited new AI model
-
Appeal board says homophobia 'commonplace' in Aussie Rules
-
Hot pants: Tokyo government workers swap suits for shorts
-
Chinese EV makers take centre stage at world's biggest auto show
-
Concern stirs Lula camp as election bid loses momentum
-
China's top AI players
-
Five things to know about Chinese AI startup DeepSeek
-
Possible Trump rescue of Spirit Airlines spurs debate
-
Wild Balkan berries keep gin taste steady as climate shifts
-
Mass MS-13 trial held at El Salvador mega-jail
-
Barcelona must live without teen star Yamal for title run-in
-
Hearts lead Old Firm as Scottish title race heads for tense finale
-
India criticizes 'poor taste' Trump post against immigrants
-
China's DeepSeek says releases long-awaited new AI model
-
Hawks fend off Knicks, Raptors pull away from Cavs to cut deficit
-
Wildfires spread towards northern Japan town
-
Israel, Lebanon extend ceasefire as Iran peace talks stall
-
'Clearly me': AI drama accused of stealing faces
-
Soviet architecture vanishes as Central Asia drifts from Moscow
-
Oil extends gains, stocks sink as peace talk hopes fade
-
'Raw and honest': India climbers face obstacles in race to the top
-
Cowgirls of Philippine rodeo tackle steers, stereotypes
-
'Godzilla Minus Zero' will show monster up close, director says
-
'Stigmatized' or 'sustainable'? Vintage sales boost sees fur return
-
YouTube offers deepfake detection to Hollywood
-
US soldier allegedly bet on Maduro operation using intel
-
Bill to legalise assisted dying in England and Wales set to fail
-
Arsenal eye return to top spot, Spurs fight for survival
-
Child vaccine catch-up drive on course to hit target: UN
-
Chinese EVs geared up to dominate world's biggest auto show
-
No.2 Korda fires 65 to grab LPGA Chevron lead
-
Raiders take quarterback Mendoza with No. 1 NFL draft pick
-
Lebanon leaders accuse Israel of war crime after journalist killed
-
Stuffed toys in US capital symbolize displaced Ukrainian children
-
Lakers' Reaves could return for game three against Rockets
-
US says Iran players welcome at World Cup amid Italy uproar
-
Images of dead Maradona rock trial of medical team
Nobel winner's ingenious chemistry could lead to cancer breakthroughs
"All kinds of crazy things" is how Carolyn Bertozzi, a 2022 Nobel laureate, describes her life's work. Actually performing "chemistry in cells and in people."
When she started her research in 1997, the Stanford professor was aiming only to observe the evolution of certain molecules on the surface of cancer cells.
Today, thanks to her discoveries, at least two companies -- including one she co-founded -- are developing innovative cancer treatments.
The multitude of applications made possible by her findings are impressive: delivering treatments with extreme precision, understanding better how drugs act inside the body, visualizing certain bacteria, to name a few.
"I can't even really enumerate them. The vast majority of those applications I would never have foreseen," she told AFP in an interview.
The Nobel Prize committee recognized Bertozzi's pioneering advances on Wednesday, making her only the eighth woman to win the chemistry prize, at just 55 years old.
- Lego pieces -
Her journey began when she found she had a passion for organic chemistry, while taking pre-medicine courses at Harvard.
The subject is notoriously -- many say fiendishly -- difficult, but she credits an "amazing professor," the late David Evans, for bringing it to life -- and changing the course of her life.
"I said, forget the med school thing. I'm going to be a chemist," said Bertozzi, whose sister is a professor of applied mathematics, and father a retired professor of physics.
After completing her post-doctorate and joining the faculty at UC Berkeley, she wanted to take a closer look at glycans: complex carbohydrates, or sugars, located on the surface of cells, which "go through structural changes" when they become cancerous.
At the time, "there was no tool to image sugars, like in a microscope, for example," she said.
She had an idea that would require two chemical substances that fit together perfectly, like pieces of lego.
The first lego is fed to cells via a sugar. The cell metabolizes it and places it on the tip of the glycan. The second piece of lego, a fluorescent molecule, is injected into the body.
The two lego pieces click together, and voila: hidden glycans reveal themselves under a microscope.
This technique is inspired by "click chemistry" developed independently by Denmark's Morten Meldal and American Barry Sharpless -- Bertozzi's co-winners. But their discoveries relied on using copper as a catalyst, which is toxic to the body.
One of Bertozzi's great leaps was achieving the same type of ultra-efficient reaction without copper.
The other tour de force: making it all happen without wreaking havoc with other processes in the body.
"The beauty of it is that you can take the two Legos and click them together, even if they're surrounded by millions of other very similar plastic toys," she explained.
She coined the term "bioorthogonal chemistry," meaning a reaction that doesn't interfere with other biochemical processes. Perfecting the technique took 10 years.
- 'Cycle of science' -
Researchers are now leveraging these breakthroughs to develop cancer treatments.
Glycans on cancer cells "are able to hide the cancer cell from the immune system -- and so your body can't fight it, it can't see it," she explains.
Using bioorthogonal chemistry, "we made a new type of medicine, which basically acts like a lawnmower," says Bertozzi.
The first lego attaches to the cancer cell's surface, and the second, which clips onto it, is equipped with an enzyme that "mows off the sugars as if they're just grass, it cuts the grass and the sugars fall off," she says with a smile.
The drug is currently being tested in the early stages of a clinical trial.
Another company is seeking to use bioorthogonal chemistry to better target cancer treatment. The first lego piece is injected into a tumor, then a second, which carries the drug, attaches itself and acts only on its target.
"So that allows the oncologist to treat the tumor and kill the tumor without exposing the person's entire body to a toxic chemical," she says.
"What the future holds is hopefully an impact in human health," says Bertozzi. "But the people who decide that more so than myself, are the students and postdocs that join my lab."
Hundreds of them, current and former, filled her email box with messages of congratulations this morning.
"That really is the cycle of science -- it's being mentored and then mentoring" she adds. And "mentoring students gives you an opportunity to amplify the impact of your science."
H.Seidel--BTB